COMPASS Pathways Inc.
NASDAQ: CMPS
Company Overview
The company's focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The team is pioneering the development of a new model of psilocybin therapy, in which their proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.
COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and the company is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America.
The company is headquartered in London, UK, with offices in New York, USA.
Financial Highlights
$0
Revenue (ttm)
$0
Gross Profit (ttm)
-$2.70
Diluted EPS (ttm)
Management Team
Mr. George Jay Goldsmith
Co-Founder, Chair of the Board & CEO
Mr. Lars Christian Wilde
Co-Founder, Pres & Chief Bus. Officer
Dr. Ekaterina Malievskaia M.D.
Co-Founder, Chief Innovation Officer & Director
Mr. Piers John Morgan
Chief Financial Officer
Mr. Nate Poulsen J.D.
Gen. Counsel & Chief Legal Officer
Mr. Stephen D. Schultz
Sr. VP of Investor Relations
Ms. Tracy Cheung
Chief Communications Officer
Mr. Marco Mohwinckel
Chief Commercial Officer
Mr. Trevor Mill
Chief Devel. Officer
Dr. Greg Ryslik Ph.D.
Sr. VP of Data Science, Machine Learning & Digital Health Research
Key Highlights
Market Capitalization
$1,250,555,542
Shares Outstanding
34,805,331
Shares Short (% of Float)
467,120 (0%)
Insider Ownership
5%